Revvity Inc (BSP:R1VT34)
R$ 23.77 0 (0%) Market Cap: 81.00 Bil Enterprise Value: 93.46 Bil PE Ratio: 56.19 PB Ratio: 1.79 GF Score: 65/100

Revvity Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 03:40PM GMT
Release Date Price: R$20
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

Great. Thanks, everyone, for joining this morning. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. I have the pleasure of welcoming Max Krakowiak, the CFO of Revvity. Thank you very much, Max, for being here.

Maxwell Krakowiak
Revvity, Inc. - Senior VP & CFO

Absolutely.

Questions & Answers

Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

Maybe it would be great for you to start out kind of set the stage first to talk about the most recent results, trends you're seeing in your business. And also, there was a slight name change and everything. Maybe talk a little bit about that.

Maxwell Krakowiak
Revvity, Inc. - Senior VP & CFO

Yes, sure. So I think if we go back to the commentary we had on the first quarter call. Q1 came in, I would say, probably at the upper end of our expectations.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot